Skip to main navigation
Skip to main content
Skip to Footer

Navigate Novartis

Global
- Novartis site directory

Our Company
Our Focus
Our Science
Careers

All News

Advanced Search Basic Search

From Date:

To Date:

Show:

All

Featured News

Media Releases

In the News

Stories

Statements

Filter By

Language:

En

Fr

De

2016

October

Media Release / Oct 08, 2016

Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

August

Media Release / Aug 03, 2016

Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer

May

Media Release / May 25, 2016

Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event

Media Release / May 18, 2016

MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer

2015

October

Media Release / Oct 27, 2015

Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance

Media Release / Oct 21, 2015

Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma

September

Media Release / Sep 24, 2015

Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires

August

Media Release / Aug 27, 2015

Novartis International BioCamp highlights how collaboration and diversity drive innovation and inspires future science leaders

June

Media Release / Jun 18, 2015

Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day

January

Media Release / Jan 07, 2015

Novartis collaborates with Intellia Therapeutics and Caribou Biosciences to explore making medicines and drug discovery tools with CRISPR genome editing technology

Search Results Navigation

First page
Previous page
Page 1 of 4
Page 2 of 4
Page 3 of 4
Current page 4 of 4

Related Links

Stay Up-to-Date
Novartis SEC Filings
Novartis Social Business Resources
What should I know before joining a clinical trial?

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

You are here

Home ›
Media

Novartis Global

Navigate Novartis
Contact Us
About Novartis
Our Portfolio
- Global Product Portfolio
- Global Clinical Pipeline
Careers
- Career Search

Subscribe to Novartis

twitter
linkedin
youtube
facebook
instagram

Novartis Site Directory

© 2019 Novartis AG

Terms of Use
Privacy Policy
Contact Us
Site Map

This site is intended for a global audience.